Company / Net Income
NovaBay Pharmaceuticals, Inc. Net Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$7.2M
FY2024
5-year range
-$11.0M / -$5.8M
FY2020-FY2024
Trend
+25.1%
vs FY2023
Sector context
#63 of 214
Health Care
What the data says
At -$7M, NovaBay Pharmaceuticals, Inc.'s net income ranks #63 of 214 in the Health Care sector. Net Income has fluctuated over the past 10 years, ranging from -$19M in FY2015 to -$6M in FY2021.
Based on SEC 10-K filings.
-$7M in FY2024.
Improved from -$11M to -$7M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#63 of 214 in Health CareTop 29% of 214This company -$7.2M Sector average $442.7M
▼
-101.6% below sector average
Key checks
Key Insights
- In FY2024, net income increased 25.1% year-over-year.
- Ranks #63 out of 214 companies in the Health Care sector.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$7.2M | +25.1% |
| FY2023 | -$9.6M | +9.1% |
| FY2022 | -$10.6M | -82.1% |
| FY2021 | -$5.8M | +47.2% |
| FY2020 | -$11.0M | -14.3% |
| FY2019 | -$9.7M | -47.6% |
| FY2018 | -$6.5M | +11.6% |
| FY2017 | -$7.4M | +43.7% |
| FY2016 | -$13.2M | +30.7% |
| FY2015 | -$19.0M | -24.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026